Clinical Trials Logo

Clinical Trial Summary

1. study the pharmacokinetics of mini-pooled intravenous immunoglobulin( MP-IVIG) 2. to determine the efficacy of intravenous immunoglobulin (IVIg) in hastening recovery and reducing the complications of Guillain-Barré syndrome (GBS). - The MP-IVIG was tolerated and presented no safety issues in a previous study and we will be confirmed by monitoring any adverse events (anaphylaxis and haemolysis) ( no or mild or moderate) and reporting them to ethical committee safety monitoring group. - Efficacy will be confirmed by: 1. Patient able to walk 2. Improvement of general health. 3. Integration in to social live 3. to compare the efficacy of IVIg to plasma exchange (PE) in hastening recovery and improving the condition of GBS

Clinical Trial Description

Guillain-Barré syndrome (GBS) is a frequent cause of neuromuscular paralysis occurring at all ages. The incidence of GBS is reported to be 1.2-2.3 per 100,000 per year . GBS is a post infectious disorder. The most frequently identified preceding infection is Campylobacter jejuni. Others are cytomegalovirus, Epstein-Barr virus, Mycoplasma pneumoniae, and Haemophilus influenzae . Many reports have documented the occurrence of GBS shortly after vaccinations, operations, or stressful events, but the causality and pathophysiology are still debated . Rapidly progressive weakness is the core clinical feature of GBS. By definition, maximal weakness is reached within 4 weeks, but most patients reach it within 2 to 3 weeks. Thereafter, patients enter a plateau phase that ranges from days to several weeks or months . This phase is followed by a usually much slower and variable recovery phase. In Europe, about one-third of GBS patients remain able to walk ("mild patients") .about 25% of the GBS patients who are unable to walk ("severe patients") need artificial ventilation. This is predominantly due to weakness of the respiratory muscles. GBS has a great impact on social life and the ability to perform activities of daily life. therefore, GBS remains a severe disease for which better treatments are required . . Magdy EL-Ekiaby, et al 2010 introduce the concept of small-scale ("minipool") plasma processing methods. The preparation of the Immunoglobulin G (IgG) plasma fractionation from 20 blood donations which are tested for anti-A and anti-B titre < 32. Implementable with minimum infrastructural requirements. They developed viral inactivation and protein purification technologies in single-use equipment to prepare virally safe solvent/detergent-filtered (S/D-F) plasma Producing a 90%pure immunoglobulin fraction in disposable single-use devices for transfusion . IVIG adverse events (AEs) are not frequent; hemolysis after IVIG is a known, rare complication. Higher doses and non-O blood group are key risk factors. The incidence of post-IVIG hemolysis is estimated at 1 per 1000 IVIG treatment episodes, most of which occur within 2 days of exposure. Although the preparation of blood group specific IVIGs in industry is a complex issue because of the pooling of thousands of plasma donations per batch, the preparation of blood group-specific mini-pool IVIG (MP-IVIG) is possible because each pool consists of only 20 plasma donations. Blood group-matched MP-IVIG is assumed to reduce the incidence of IVIG-associated hemolysis, which is largely caused by the presence of anti-A and anti-B agglutinins reacting with non-O blood group recipients. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04550611
Study type Interventional
Source Assiut University
Contact Hend A Moubark, Specialist
Phone 01010326577
Status Not yet recruiting
Phase N/A
Start date November 2021
Completion date December 2022

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04053452 - Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome N/A
Recruiting NCT02582853 - sCD163 as a Potential Biomarker in Guillain- Barré Syndrome N/A
Completed NCT00056810 - Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine Phase 2
Completed NCT05104762 - IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients Phase 2/Phase 3
Recruiting NCT05630313 - Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil
Recruiting NCT03801135 - Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation N/A
Active, not recruiting NCT01655394 - Change of Nerve Conduction Properties in IVIg Dependent Neuropathies N/A
Completed NCT04927598 - Predictors and Prognostic Factors of Gullian Barrie Syndrome Outcome
Completed NCT06334796 - Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology Early Phase 1
Not yet recruiting NCT04092140 - Neuromuscular Ultrasound in Correlation to Neurophysiological Findings
Withdrawn NCT03268304 - Feasibility of Two New Software Modules for the Rehabilitation of Patients With Neuromuscular Upper Limb Impairments
Not yet recruiting NCT05701189 - Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome Phase 2
Withdrawn NCT02459808 - Gastrointestinal Transit Time in Patients With Guillain-Barré Syndrome N/A
Completed NCT04752566 - A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome Phase 3
Completed NCT05292690 - An Assistive Powered Wheelchair: Stage 2 Trial
Not yet recruiting NCT06300359 - Prognostic Indicators of Gullian-Barre Syndrome
Completed NCT00575653 - Safety Study of GBS Following Menactra Meningococcal Vaccination N/A
Completed NCT05491096 - Effects of Proprioceptive Neuromuscular Training on Sensory and Motor Function in Guillain Barre Syndrome N/A
Not yet recruiting NCT05114941 - Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome N/A
Completed NCT05945784 - Exploring Accessible Beauty for Individuals With Upper Extremity Deficits